Loxo Oncology

NASDAQ

- -

- -

- -

- -

- -

- -

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers primarily in the United States. The company’s lead product candidate comprises LOXO-101, an oral and selective inhibitor of tropomyosin receptor kinase (TRK), which is in Phase I clinical trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. Its preclinical programs include RET inhibitor that optimizes potency for RET fusion proteins, mutations, and clinically-identified resistance mutations; and FGFR inhibitor that optimizes on potency against receptors comprising four isoforms with tyrosine kinase domains. The company has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.